Inflammatory disease Archives

inflammatory bowel disease treatment personalized medicine predictimmune

News and Trends 31 Jul 2019

British Biotech Raises €11M to Market Personalized Medicine Test

The UK biotech PredictImmune has raised €11M (£10M) in a Series B fundraising round to commercialize technology to predict the progress of inflammatory bowel disease in newly diagnosed patients. The funds will finance the global launch of PredictSURE IBD, a blood test that can identify patients with the most severe cases of inflammatory bowel disease, […]

July 31, 2019 - 3 minutesmins - By Jonathan Smith

More News! 25 Jul 2019

German Biotech Breath Therapeutics Acquired in Deal Worth up to €500M

The Italian company Zambon has acquired the German biotech Breath Therapeutics for up to €500M, getting hold of its treatment for a rare lung disease known as popcorn lung. The deal includes an upfront payment of €140M and up to €360M upon reaching undisclosed regulatory milestones. Zambon will take over the development of a treatment […]

July 25, 2019 - 2 minutesmins - By Jonathan Smith

gilead galapagos arthritis pulmonary fibrosis

News and Trends 15 Jul 2019

Gilead Pays Billions for Access to Galapagos’ Pipeline

Gilead has launched a 10-year collaboration with the Belgo-Dutch biotech Galapagos, paying at least €4.5B ($5.1B) for commercial rights to Galapagos’s whole pipeline, including a phase III drug for pulmonary fibrosis. As part of the deal, Gilead will pay Galapagos €3.5B ($3.95B) upfront, with a further €1B ($1.1B) in equity investment. In return, Gilead gets […]

July 15, 2019 - 2 minutesmins - By Jonathan Smith

lupus autoimmune disease neutrophil citryll

News and Trends 4 Jul 2019

Dutch Antibodies for Autoimmune Diseases Boosted by €15M Series A

The Dutch biotech Citryll has raised €15M to develop antibodies that could fight autoimmune and inflammatory diseases more effectively than current treatments by inhibiting the innate immune system. The Series A funds will be used to launch the clinical development of Citryll’s lead antibody, which is designed to treat the autoimmune condition lupus. The money […]

July 4, 2019 - 2 minutesmins - By Jonathan Smith

inflarx trial inflammatory disease fail skin

More News! 6 Jun 2019

Shares Drop 90% as Antibody for Inflammatory Skin Disease Fails Phase II

The German company InflaRx has seen its shares on the Nasdaq plummet after announcing that its treatment for an inflammatory skin disease failed to beat the placebo in a phase IIb trial. The trial had enrolled 179 patients with hidradenitis suppurativa, an incurable condition causing painful lumps on the skin. By the 16th week of […]

June 6, 2019 - 2 minutesmins - By Jonathan Smith

microbiome fecal transplant maat pharma enterobiotix

News and Trends 22 May 2019

Microbiome Companies Unite to Push for EU Regulation Reform

European microbiome biotechs have launched a collaboration to streamline the EU’s regulatory pathways for microbiome-based treatments, which have the potential to treat inflammatory disease and bacterial infection. The companies will propose EU regulatory changes that make it easier to commercialize treatments based on targeting a patient’s microbiome bacteria. Microbiome-based treatments form a young field in […]

May 22, 2019 - 2 minutesmins - By Jonathan Smith

Best in Biotech 8 May 2019

Top 10 Biotechs in Lausanne

The Swiss city of Lausanne is perhaps best known as a hub of international sport, but what many outsiders may not realize is that it’s also one of Switzerland’s biggest biotech hubs. Many of the biotechs in the city are connected to the University of Lausanne (UNIL), as well as the renowned Swiss Federal Institute […]

May 8, 2019 - 7 minutesmins - By David Cox

Galapagos Gilead filgotinib rheumatoid arthritis

News and Trends 29 Mar 2019

Galapagos Nears First Drug Approval with Phase III Success in Rheumatoid Arthritis

Galapagos has released positive data from two phase III trials testing its flagship drug candidate, filgotinib, that will let the company and its partner Gilead apply for marketing approval. 20 years after its foundation, Galapagos is finally approaching the finish line. Yesterday, the company has shared positive data from two clinical trials that together enrolled […]

March 29, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

arthritis pediatric juvenile idiopathic Leuven

News and Trends 13 Mar 2019

Artificial Intelligence Detects Juvenile Arthritis in the Blood

Using artificial intelligence, a Belgian research group can diagnose juvenile arthritis from blood samples with almost 90% accuracy and identify different forms of the disease, something that is not currently possible. Juvenile idiopathic arthritis causes joint pain, swelling and stiffness in children under the age of 16. The disease is hard to treat because there […]

March 13, 2019 - 3 minutesmins - By Jonathan Smith

osteoarthritis stem cell regenerative medicine

News and Trends 12 Mar 2019

Stem Cells and Hydrogel Make Potential Osteoarthritis Treatment

Scientists from the Netherlands have received a €600,000 grant to test a treatment for osteoarthritis in humans that combines hydrogels and stem cells to help the knee joint heal. In osteoarthritis, the cartilage in joints such as the knees breaks down, causing stiffness and pain. There is no cure at the moment, and most current […]

March 12, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 8 Mar 2019

HIV Drug Shows Promise for Treating Ulcerative Colitis Patients

A small molecule drug, developed by the company Abivax for treating HIV, has also shown promise for patients with the inflammatory bowel disease ulcerative colitis, reducing the disease severity consistently for over six months. Abivax tested the drug on patients with moderate-to-severe cases of ulcerative colitis, an inflammatory bowel condition that causes rectal bleeding and […]

March 8, 2019 - 3 minutesmins - By Jonathan Smith

PharmaBiome microbiome ulcerative colitis

Interview 23 Jan 2019

Tackling the Complexity of the Gut Microbiome for Better Treatments

An imbalance in gut microbe species is linked with gastrointestinal disease. Philip talked with the CEO and co-founder of the Swiss startup PharmaBiome, Tomas de Wouters, about the complexity of rebalancing the gut microbiome in these conditions. The microbiome is a hugely complex ecosystem of microbes living all around the body. Different parts of the […]

January 23, 2019 - 5 minutesmins - By Jonathan Smith

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us